The First International Symposium on Pheochromocytoma ... the most accurate screening approach, was recommended as the first-line test for diagnosis; reference intervals should favor sensitivity ...

In analogy, the screening for pheochromocytoma in patients with von Hippel Lindau disease is recommended at age 4 years, considering that there also are “asymptomatic” individuals with ...

In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...

Recently case reports have appeared in which both benzodioxane and dibenamine were effective in lowering the blood pressure to normal in a patient subsequently proved to have a pheochromocytoma.

Low-osmolar, contrast-enhanced CT can be safely used in patients with pheochromocytoma. “This tool will enhance physicians' abilities to diagnose and treat patients with pheochromocytoma ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Many thanks for this valuable additional information on screening, regarding the significance of pheochromocytoma in neurofibromatosis. The incidence of these rare tumors stated in the literature ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

the current WHO nomenclature reserves the term 'pheochromocytoma' for paragangliomas of adrenal origin Measurements of plasma or urinary fractionated metanephrines are the most accurate screening ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.